DAVID Transcutaneous Jaundice Detector
Handheld transcutaneous bilirubinometer with dual-wavelength, dual optical-path measurement — corrects for melanin and dermal thickness; up to 2,000 measurements per charge.
Single-wavelength transcutaneous bilirubinometers carry documented systematic error related to skin pigmentation and dermal thickness, limiting their reliability across diverse neonatal populations. The DAVID detector applies a dual optical-path, dual-wavelength measurement principle that simultaneously corrects for melanin content and dermis thickness, supporting transcutaneous bilirubin (TcB) as a reliable screening tool. The device supports up to 2,000 measurements per charge and stores multi-patient datasets for trend tracking at the point of care.
- Non-invasive bilirubin screening — Removes the need for heel lance or venipuncture in routine surveillance.
- Dual optical-path, dual-wavelength correction — Simultaneous correction for melanin and dermis thickness.
- 2,000 measurements per charge — Full-shift deployment without battery interruption.
- Xenon flash lamp >150,000 measurements — Calibrated illumination across operational life.
- Handheld, point-of-care form factor.
- On-device patient datasets for trend tracking.
- Reduces phlebotomy workload across postnatal and NICU surveillance pathways.
Used for routine bilirubin screening in postnatal and NICU neonates, including populations with diverse skin pigmentation. Enables non-invasive, repeatable TcB measurement to inform decisions about phototherapy initiation and escalation.
